The relationship between serum adipokine fibroblast growth factor‐21 and gestational diabetes mellitus

Jia, Xiaojiao; Bai, Liwei; Ma, Ning; Lu, Qiang

doi:10.1111/jdi.13889

Cited by 4 publications

(3 citation statements)

References 24 publications

(29 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…These observations were confirmed by Jia et al, who showed significantly higher FGF21 levels in GDM patients than in healthy controls. In addition, they observed that FGF21 levels in this group were related to prepregnancy BMI, weight gain during pregnancy, leptin, RBP-4 (retinol binding protein 4), and adiponectin in GDM, although leptin, RBP-4, and adiponectin levels were comparable in both groups [133].…”

Section: Fgf19 Family In Gdmmentioning

confidence: 87%

The Role of the FGF19 Family in the Pathogenesis of Gestational Diabetes: A Narrative Review

Sadowska,

Poniedziałek-Czajkowska,

Mierzyński

2023

IJMS

View full text Add to dashboard Cite

Gestational diabetes mellitus (GDM) is one of the most common pregnancy complications. Understanding the pathogenesis and appropriate diagnosis of GDM enables the implementation of early interventions during pregnancy that reduce the risk of maternal and fetal complications. At the same time, it provides opportunities to prevent diabetes, metabolic syndrome, and cardiovascular diseases in women with GDM and their offspring in the future. Fibroblast growth factors (FGFs) represent a heterogeneous family of signaling proteins which play a vital role in cell proliferation and differentiation, repair of damaged tissues, wound healing, angiogenesis, and mitogenesis and also affect the regulation of carbohydrate, lipid, and hormone metabolism. Abnormalities in the signaling function of FGFs may lead to numerous pathological conditions, including metabolic diseases. The FGF19 subfamily, also known as atypical FGFs, which includes FGF19, FGF21, and FGF23, is essential in regulating metabolic homeostasis and acts as a hormone while entering the systemic circulation. Many studies have pointed to the involvement of the FGF19 subfamily in the pathogenesis of metabolic diseases, including GDM, although the results are inconclusive. FGF19 and FGF21 are thought to be associated with insulin resistance, an essential element in the pathogenesis of GDM. FGF21 may influence placental metabolism and thus contribute to fetal growth and metabolism regulation. The observed relationship between FGF21 and increased birth weight could suggest a potential role for FGF21 in predicting future metabolic abnormalities in children born to women with GDM. In this group of patients, different mechanisms may contribute to an increased risk of cardiovascular diseases in women in later life, and FGF23 appears to be their promising early predictor. This study aims to present a comprehensive review of the FGF19 subfamily, emphasizing its role in GDM and predicting its long-term metabolic consequences for mothers and their offspring.

show abstract

Section: Fgf19 Family In Gdmmentioning

confidence: 87%

The Role of the FGF19 Family in the Pathogenesis of Gestational Diabetes: A Narrative Review

Sadowska,

Poniedziałek-Czajkowska,

Mierzyński

2023

IJMS

View full text Add to dashboard Cite

show abstract

“…GDM is a common complication during pregnancy, with obesity and insulin resistance being the major contributing factors [ 2 , 8 ]. The development of GDM may involve the release of cytokines and chemokines from adipose tissue [ 14 ].…”

Section: Discussionmentioning

confidence: 99%

“…Gestational diabetes mellitus (GDM) stands out as a highly prevalent complication encountered during the course of pregnancy [ 1 ]. The chief etiological factors responsible for GDM are glucose intolerance and insulin resistance [ 2 ]. During the second trimester, insulin resistance is accentuated, which results in elevated blood glucose levels that support fetal growth.…”

Section: Introductionmentioning

confidence: 99%

A positive association of serum CCN5/WISP2 levels with the risk of developing gestational diabetes mellitus: a case–control study

Hamdan Alshganbee,

Nabatchian,

Farrokhi

et al. 2023

J Physiol Sci

View full text Add to dashboard Cite

Introduction CCN5/WISP2 is prominently manifest in adipose tissue and has been linked to the pathogenesis of obesity, diabetes, and insulin resistance. However, discrepancies exist in previous studies, and little is known about its association with gestational diabetes mellitus (GDM). The current investigation is designed to examine the correlation of WISP2 with risk factors in GDM patients in comparison to healthy pregnant women for the first time. Methods This case–control study measured serum levels of CCN5, TNF-α, IL-6, adiponectin, and fasting insulin using ELISA kits in 88 GDM patients and 88 pregnant women. Results The GDM group had remarkably higher serum levels of CCN5 (379.41 ± 83.078 ng/ml) compared to controls (212.02 ± 77.935 ng/ml). In a similar vein, it was observed that patients diagnosed with GDM exhibited elevated levels of pro-inflammatory cytokines such as IL-6 and TNF-α; while conversely, adiponectin levels were found to be significantly lower than those observed in the control group (P < 0.0001). In women with GDM, a positive and significant correlation was observed between CCN5 and BMI, FBG, insulin, HOMA-IR, as well as IL-6 and TNF-α levels. In the adjusted model, the risk of GDM was significantly increased with elevated serum CCN5 level. Conclusion Our research indicates a noteworthy and affirmative correlation between the levels of CCN5 in the serum and the risk of developing GDM, along with its associated risk factors such as BMI, insulin resistance index, FBG, and inflammatory cytokines (TNF-α and IL-6). These findings suggest that CCN5 could potentially play a role in the etiology of GDM.

show abstract

Retinol-binding protein 4 (RBP4) circulating levels and gestational diabetes mellitus: a systematic review and meta-analysis

Leca,

Kite,

Lagojda

et al. 2024

Front. Public Health

View full text Add to dashboard Cite

BackgroundGestational diabetes mellitus (GDM) is a prevalent condition where diabetes is diagnosed during pregnancy, affecting both maternal and fetal outcomes. Retinol-binding protein 4 (RBP4) is a circulating adipokine which belongs to the lipocalin family and acts as a specific carrier protein that delivers retinol (vitamin A) from the liver to the peripheral tissues. Growing data indicate that circulating RBP4 levels may positively correlate with GDM. Thus, this systematic review and meta-analysis aimed to investigate the potential relationship between circulating RBP4 levels and GDM when measured at various stages of pregnancy.MethodsMEDLINE, CINAHL, EMCARE, EMBASE, Scopus, and Web of Science databases were searched to identify studies comparing pregnant women with and without GDM, whose circulating RBP4 levels were measured in at least one pregnancy trimester. Findings were reported using standardized mean difference (SMD) and random-effects models were used to account for variability among studies. Furthermore, the risk of bias was assessed using the RoBANS tool.ResultsOut of the 34 studies identified, 32 were included in the meta-analysis (seven with circulating RBP4 levels measured in the first trimester, 19 at 24–28 weeks, and 14 at >28 weeks of pregnancy). RBP4 levels were statistically higher in the GDM group than in controls when measured during all these pregnancy stages, with the noted RBP4 SMD being 0.322 in the first trimester (95% CI: 0.126–0.517; p < 0.001; 946 GDM cases vs. 1701 non-GDM controls); 0.628 at 24–28 weeks of gestation (95% CI: 0.290–0.966; p < 0.001; 1776 GDM cases vs. 1942 controls); and 0.875 at >28 weeks of gestation (95% CI: 0.252–1.498; p = 0.006; 870 GDM cases vs. 1942 non-GDM controls). Significant study heterogeneity was noted for all three pregnancy timepoints.ConclusionThe present findings indicate consistently higher circulating RBP4 levels in GDM cases compared to non-GDM controls, suggesting the potential relevance of RBP4 as a biomarker for GDM. However, the documented substantial study heterogeneity, alongside imprecision in effect estimates, underscores the need for further research and standardization of measurement methods to elucidate whether RBP4 can be utilized in clinical practice as a potential GDM biomarker.Systematic review registrationPROSPERO (CRD42022340097: https://www.crd.york.ac.uk/prospero/display_record.php?ID=CRD42022340097).

show abstract

The relationship between serum adipokine fibroblast growth factor‐21 and gestational diabetes mellitus

Cited by 4 publications

References 24 publications

The Role of the FGF19 Family in the Pathogenesis of Gestational Diabetes: A Narrative Review

The Role of the FGF19 Family in the Pathogenesis of Gestational Diabetes: A Narrative Review

A positive association of serum CCN5/WISP2 levels with the risk of developing gestational diabetes mellitus: a case–control study

Retinol-binding protein 4 (RBP4) circulating levels and gestational diabetes mellitus: a systematic review and meta-analysis

Contact Info

Product

Resources

About